Patricia A. Young, M.D.
The Irving Feintech Family Foundation Research Grant
Research Title: Molecular and immunologic correlates of responses to anti-CD 19 chimeric antigen receptor T cell therapy
Mentor: John M. Timmerman
CD 19 is a protein on the surface of B cells and serves as a potential target in advanced non-Hodgkin lymphomas and leukemias. One experimental treatment has been anti-CD 19 chimeric antigen receptor (CAR) T cells, which uses the patientâ€™s T cells to engineer an anti-CD 19 portion to specifically recognize and kill CD 19-expressing cells. A clinical trial using anti-CD 19 CAR T cells will be implemented at UCLA in the summer of 2014. We plan to: 1) initiate a phase I clinical trial using transfer of engineered T cells, and 2) perform laboratory studies to improve upon and understand the mechanisms of this treatment.